BioSpace News Archive

Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected by Servier Pharmaceuticals to be a specialty pharmacy partner for TIBSOVO® (ivosidenib), which is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with newly diagnosed acute myeloid leukemia.

EGF Theramed Health Corp. (CSE: TMED) (OTC Pink: EVAHF) (FSE: AUHP) (the “Company” of “EGF”) has secured a term sheet agreement with Reef Capital, pursuant to which the lender will loan up to $10-million to EGF Theramed in ten tranches of $500,000.00 each.

Terumo Cardiovascular, a global leader in medical devices for cardiac and vascular surgery, marked the opening of its newest manufacturing plant in La Lima, Cartago, Costa Rica.

A single research test has the potential to predict which patients treated with immunotherapies – which harness the immune system to attack cancer cells – are likely to have their cancer recur or have severe side effects, a new study found.

Caravan Biologix, Inc., a developer of novel cell-derived vesicle (CDV) therapeutics targeting specific cancers and gene therapy-related diseases, today announced that it has entered into an agreement with Seoul-based MDimune Inc. to apply their nanovesicle technology to enhance the effects of chimeric antigen receptor-expressing natural killer (CAR-NK) cells on various solid tumor cancers.

Align Technology, Inc., a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM services for orthodontic and restorative dentistry, announced the official opening of the first Europe, Middle East & Africa regional manufacturing facility in Wroclaw, Poland.

GigaGen Inc. announced today it has entered into a contract with the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to demonstrate the utility of its first-in-class recombinant human polyclonal antibody discovery platform against biological threats of interest to the DOD.

Antisense and RNAi therapeutics the new class of drugs that apply their impact either by hushing a piece of RNA using short meddling RNAs (siRNAs) or microRNAs (miRNAs) which is engaged with causing the sickness or instigates the debasement of designated mRNA by RNase and in this manner decreasing the interpretation of unfortunate protein

CAR T cell therapy is considered as an extremely effective strategy for the treatment of patients experiencing blood malignant growth and has effectively experienced other methods of disease treatment like chemotherapy.

Drug repurposing, also known as drug re-profiling or drug re-positioning, refers to research regarding a biologic agent or a compound that can effectively treat one condition to see whether it can safely and effectively treat other health conditions or diseases.